Charnwood Molecular acquires 62,500 sq ft at Loughborough Science Park

Cushman & Wakefield and Mather Jamie have completed the letting of 62,500 sq ft of state-of-the-art laboratory and office space at Charnwood Campus in Loughborough.

Leading UK-based Contract Research Organisation (CRO), Charnwood Molecular, which services the global pharmaceutical and biotechnology market, has acquired the space as part of significant expansion plans for the year ahead.

The company will solely occupy Building 42 at the campus, having previously been based at BioCity in Nottingham. The three-storey, state-of-the-art laboratory facility forms part of Charnwood Campus – a science, innovation and technology park set in 70 acres of landscaped grounds in Loughborough. The campus was recently designated a ‘Life Sciences Opportunity Zone’, providing an environment to inspire discovery, encourage collaboration and accelerate business growth within the Med-Tech and Biopharma industries.

Cushman & Wakefield and Mather Jamie acted on behalf of Charnwood Campus to agree the deal which closely follows the letting of Building 31 to Kindeva Drug Delivery which took 15,000 sq ft of space in March 2021.

Scott Rutherford, Partner in Cushman & Wakefield’s National Offices team, said: “Charnwood Molecular are a fantastic addition to the Campus and will occupy truly world-class facilities. The lettings to both Charnwood Molecular and Kindeva reinforce the East Midlands’ and Loughborough’s reputation for outstanding pharmaceutical research and development and have capitalised on the exceptional opportunities of existing accommodation at the park which are ready to be optimised.”

Gosia Khrais, Commercial and Marketing Director at Charnwood Campus, said: “It is a great pleasure to welcome Charnwood Molecular as a new occupier here. This fantastic CRO with ambitious growth plans will cement life sciences as a priority sector in the region, create jobs and help us grow our local economy. It is really great news for Loughborough.”

Steve Allin, CEO of Charnwood Molecular, commented: “The truly world-class facilities at Charnwood Campus provide us with a key piece in our strategic plan to become the provider of choice for integrated drug discovery and development services within the global life sciences sector. The new laboratories will provide substantial capacity for future growth and expansion of our medicinal chemistry and process research teams, along with the addition of related drug discovery service lines.”